🔗 Share this article

The recently developed medications for gonorrhoea in many years are being viewed as a "major milestone" in the fight against superbug strains of the bacteria, according to health experts.

An International Public Health Issue

Gonorrhoea infections are on the rise globally, with figures suggesting more than 82 million new cases annually. Notably increased rates are reported in the African continent and nations within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. Within England, cases have hit a all-time high, while rates across Europe in 2023 were triple the level compared to the rates from 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary advancement in the face of growing infection rates, the spread of superbugs and the very limited therapeutic options presently on offer.”

Medical experts are deeply concerned about the rise in antibiotic-resistant strains. The WHO has classified it as a "priority pathogen". A tracking program showed that the effectiveness of standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Treatment Options Gain Clearance

One new antibiotic, alternatively called Nuzolvence, was authorized by the American regulatory agency in December for use against gonorrhoea. This infection can lead to major issues, including infertility. Experts hope that specific application of this new drug will help delay the development of resistance.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, gained clearance in the same week. This drug, which is also used to treat urinary tract infections, was proven in research to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Partnership

This new treatment stemmed from a new, not-for-profit approach for antibiotic development. The non-profit organisation GARDP worked alongside the pharmaceutical company Innoviva to develop it.

“This milestone marks a significant shift in the therapy of multidrug-resistant gonorrhoea, which up to this point has been outpacing medical innovation.”

Clinical Trial Results and Worldwide Availability

Based on findings detailed in a major medical journal, the new drug successfully treated over nine in ten of genital gonorrhoea infections. This puts it on an comparable level with the typical regimen, which uses two antibiotics. The research included hundreds of participants from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, the non-profit has the rights to license and sell the drug in numerous developing nations.

Medical professionals directly involved have voiced optimism. Access to a single-dose, oral treatment such as this is seen as a "game-changer" for gonorrhoea control. This is considered vital to reduce the burden of the infection for patients and to halt the transmission of untreatable gonorrhoea around the world.